Neutral · 55/100Aug 13, 6:02 PM EDT
BridgeBio's KKR Affiliate to Sell 5M Shares in Secondary Offering
BBIO
BridgeBio Pharma (BBIO) announced that KKR Genetic Disorder L.P. will sell 5 million shares in a secondary public offering. The company itself is not selling shares and will not receive proceeds from the offering, which may signal investor sentiment and potent…
- ▹Secondary offering by KKR affiliate creates overhang, but no FDA negative and company has multiple assets.
- ▹Single-asset risk moderate, but dilution risk from secondary offering weighs on narrative.